Study to Evaluate the Safety and Tolerability of AD-NP1 in Healthy Human Adult Volunteers
A Phase 1 Single-blind, Placebo-controlled, Dose Escalation Study to Evaluate the Safety of AD-NP1, a Humanized Monoclonal Antibody Targeting Human ENPP1
Studie Overzicht
Toestand
Toestand
Conditie
Conditie
Interventie / Behandeling
Interventie / Behandeling
Studietype
Studietype
Inschrijving (Geschat)
Inschrijving
Fase
Fase
- Fase 1
Contacten en locaties
Studie Locaties
-
-
California
-
Los Angeles, California, Verenigde Staten, 90095
- UCLA Clinical and Translational Research Center
-
-
Deelname Criteria
Geschiktheidscriteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
- Volwassen
- Oudere volwassene
Accepteert gezonde vrijwilligers
Beschrijving
Inclusion Criteria:
- Body weight ≤ 90kg
- Ability to understand and the willingness to sign a written informed consent document
- Study subject must have read, understood, and provided written informed consent and HIPAA authorization after the nature of the study has been fully explained
- Be in general good health without history of any of the conditions listed in exclusion criteria
- No use of any tobacco products for at least 6 months
- Woman/women of childbearing potential (WOCBP) must agree not to become pregnant from the time of study enrollment until at least 6 months after the completion of the monoclonal antibody infusion. If a WOCBP is sexually active and has no history of hysterectomy or tubal ligation, she must agree to use hormonal or barrier birth control with spermicidal gel
- Sexually active male subjects must use a barrier method of contraception during the study
Screening laboratory values must meet the following criteria:
- WBC (>3,000 - <11,000/mm^3)
- Platelets (>100,000/mm^3)
- Hemoglobin (>10.5 gm/dl)
- Creatinine (<1.1 x upper limit of normal [ULN])
- BUN (<1.25 x ULN)
- AST (<1.1 x ULN)
- ALT (<1.1 x ULN)
- Alkaline Phosphatase (<1.1 x ULN)
- Bilirubin (<1.1 x ULN)
- Glucose-non-fasting (> 60 mg/dl and < 115 mg/dl)
- Human immunodeficiency virus (HIV)-infected individuals on effective antiretroviral therapy with undetectable viral load within 6 months are eligible for this trial
- For subjects with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated
- Individuals with a history of hepatitis C virus (HCV) infection must have been treated and cured. For individuals with HCV infection who are currently on treatment are eligible if they have an undetectable HCV viral load
Exclusion Criteria:
- Previous exposure to humanized or human monoclonal antibodies whether FDA approved or investigational
- Weight > 90 kg
- History of any of the following illnesses or conditions:
- a. Respiratory condition (such as asthma requiring daily medication)
- b. Clinically immunocompromised due to any primary immune or autoimmune deficiency, as a result of chronic disease, cancer or medication used to treat these diseases
- c. Blood dyscrasias
- d. Psychiatric disorder that precludes compliance with the clinical protocol
- e. Hepatitis
- Any chronic condition requiring daily prescription or over-the-counter medicine except for vitamins and birth control products
- History of drug or alcohol abuse within previous 12 months or a positive urine toxicology screen within 24 hours of initial screening
- History of a previous severe allergic reaction with generalized urticaria, angioedema, or anaphylaxis
- Physical finding on examination considered clinically significant such as heart murmur (other than functional), hepatosplenomegaly, lymphadenopathy, or focal neurological deficit
- Urinalysis positive for > trace protein, >5 RBC/HPF or >5 WBC/HPF
- Positive serology for HIV antibody, HCV antibody or Hepatitis B surface antigen
- Positive serum pregnancy test during screening or positive urine pregnancy test within 24 hours of monoclonal antibody administration, or an unwillingness to undergo pregnancy testing
- Currently breast-feeding
- Receipt of an FDA approved vaccine or any investigational study agent within previous 30 days
- Any other condition that in the opinion of the investigator would jeopardize the safety or rights of the subject participating in the study
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Fundamentele wetenschap
- Toewijzing: Gerandomiseerd
- Interventioneel model: Sequentiële toewijzing
- Masker: Enkel
Aantal wapens
Wapens en interventies
Deelnemersgroep / ArmDeelnemersgroep / Arm |
Interventie / BehandelingInterventie / Behandeling |
|---|---|
|
Experimenteel: Cohort 1 - AD-NP1 (30mg/kg)
Subjects receive a single intravenous dose of AD-NP1 at 30 mg/kg
|
AD-NP1 is a humanized monoclonal antibody targeting the catalytic domain of human ENPP1.
It is administered intravenously at escalating doses (30 mg/kg, 40 mg/kg, 60 mg/kg, and 100 mg/kg).
|
|
Placebo-vergelijker: Cohort 1 - Placebo
Subjects receive a single intravenous dose of placebo matched in volume to the 30 mg/kg dose of AD-NP1
|
Placebo is a normal saline solution administered intravenously in volumes matched to the corresponding AD-NP1 doses (30 mg/kg, 40 mg/kg, 60 mg/kg, and 100 mg/kg)
|
|
Experimenteel: Cohort 2 - AD-NP1 (40 mg/kg)
Subjects receive a single intravenous dose of AD-NP1 at 40 mg/kg
|
AD-NP1 is a humanized monoclonal antibody targeting the catalytic domain of human ENPP1.
It is administered intravenously at escalating doses (30 mg/kg, 40 mg/kg, 60 mg/kg, and 100 mg/kg).
|
|
Placebo-vergelijker: Cohort 2 - Placebo
Subjects receive a single intravenous dose of placebo matched in volume to the 40 mg/kg dose of AD-NP1
|
Placebo is a normal saline solution administered intravenously in volumes matched to the corresponding AD-NP1 doses (30 mg/kg, 40 mg/kg, 60 mg/kg, and 100 mg/kg)
|
|
Experimenteel: Cohort 3 - AD-NP1 (60 mg/kg)
Subjects receive a single intravenous dose of AD-NP1 at 60 mg/kg
|
AD-NP1 is a humanized monoclonal antibody targeting the catalytic domain of human ENPP1.
It is administered intravenously at escalating doses (30 mg/kg, 40 mg/kg, 60 mg/kg, and 100 mg/kg).
|
|
Placebo-vergelijker: Cohort 3 - Placebo
Subjects receive a single intravenous dose of placebo matched in volume to the 60 mg/kg dose of AD-NP1
|
Placebo is a normal saline solution administered intravenously in volumes matched to the corresponding AD-NP1 doses (30 mg/kg, 40 mg/kg, 60 mg/kg, and 100 mg/kg)
|
|
Experimenteel: Cohort 4 - AD-NP1 (100 mg/kg)
Subjects receive a single intravenous dose of AD-NP1 at 100 mg/kg
|
AD-NP1 is a humanized monoclonal antibody targeting the catalytic domain of human ENPP1.
It is administered intravenously at escalating doses (30 mg/kg, 40 mg/kg, 60 mg/kg, and 100 mg/kg).
|
|
Placebo-vergelijker: Cohort 4 - Placebo
Subjects receive a single intravenous dose of placebo matched in volume to the 100 mg/kg dose of AD-NP1
|
Placebo is a normal saline solution administered intravenously in volumes matched to the corresponding AD-NP1 doses (30 mg/kg, 40 mg/kg, 60 mg/kg, and 100 mg/kg)
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Safety and tolerability of escalating doses of a single IV dose of AD-NP1
Tijdsspanne: Day of infusion (Day 0) to 28 days post-dose
|
Assessed by the incidence of treatment-related Adverse Events (AEs) using the Common Terminology Criteria for Adverse Events (CTCAE) v5.0.
|
Day of infusion (Day 0) to 28 days post-dose
|
Secundaire uitkomstmaten
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Maximum Tolerated Dose of AD-NP1
Tijdsspanne: Day of infusion (Day 0) to 28 days post-dose
|
To be determined based on dose limiting toxicities (DLTs) and adverse events
|
Day of infusion (Day 0) to 28 days post-dose
|
|
Maximum Plasma Concentration (Cmax) as a pharmacokinetics (PK) parameter
Tijdsspanne: Baseline (pre-dose) up to Day 60 post-dose
|
Peak plasma concentration obtained directly from the experimental data points, to be measured in Nanograms per milliliter (ng/mL)
|
Baseline (pre-dose) up to Day 60 post-dose
|
|
Time to Maximum Plasma Concentration (Tmax) as a pharmacokinetics (PK) parameter
Tijdsspanne: Baseline (pre-dose) up to Day 60 post-dose
|
Tmax presents the time at which Cmax is observed, to be measured in hours (h) and minutes (m)
|
Baseline (pre-dose) up to Day 60 post-dose
|
|
Area Under the Plasma Concentration-Time Curve (AUC) as a pharmacokinetics (PK) parameter
Tijdsspanne: Baseline (Pre-dose), 30 minutes, 1, 2, 4, 6 hours, and Days 1, 3, 7, 14, 28, 60 post-dose.
|
AUC calculated using the linear-log trapezoidal rule from time zero (pre-dose) to the last quantifiable concentration point to be measured in Nanogram x hours per milliliter (ng * h/mL)
|
Baseline (Pre-dose), 30 minutes, 1, 2, 4, 6 hours, and Days 1, 3, 7, 14, 28, 60 post-dose.
|
|
Terminal Elimination Half-life (T(1/2)) as a pharmacokinetics (PK) parameter
Tijdsspanne: Baseline (pre-dose) up to Day 60 post-dose
|
The rate at which Ad-NP1 is cleared from the systemic plasma circulation, to be measured in Liters per hour (L/h) or Milliliters per minute per kilogram (mL/min/kg)
|
Baseline (pre-dose) up to Day 60 post-dose
|
|
Total Body Clearance (CL) as a pharmacokinetics (PK) parameter
Tijdsspanne: Baseline (pre-dose) up to Day 60 post-dose
|
The rate at which AD-NP1 is cleared from the systemic plasma circulation, to be measured in Liters per hour (L/h) or Milliliters per minute per kilogram (mL/min/kg)
|
Baseline (pre-dose) up to Day 60 post-dose
|
|
Plasma Uridine Concentration
Tijdsspanne: Baseline (pre-dose), and Days 1, 3, 7, 14, and 28 post-dose.
|
Plasma concentrations of uridine will be quantified using Liquid Chromatography-Mass Spectrometry (LC/MS).
|
Baseline (pre-dose), and Days 1, 3, 7, 14, and 28 post-dose.
|
|
Plasma Cytidine Concentration
Tijdsspanne: Baseline (pre-dose), and Days 1, 3, 7, 14, and 28 post-dose.
|
Plasma concentrations of cytidine will be quantified using Liquid Chromatography-Mass Spectrometry (LC/MS)
|
Baseline (pre-dose), and Days 1, 3, 7, 14, and 28 post-dose.
|
|
Plasma Orotidine Concentration
Tijdsspanne: Baseline (pre-dose), and Days 1, 3, 7, 14, and 28 post-dose.
|
Plasma concentrations of orotidine will be quantified using Liquid Chromatography-Mass Spectrometry (LC/MS)
|
Baseline (pre-dose), and Days 1, 3, 7, 14, and 28 post-dose.
|
|
Plasma Adenine Concentration
Tijdsspanne: Baseline (pre-dose), and Days 1, 3, 7, 14, and 28 post-dose.
|
Plasma concentrations of adenine will be quantified using Liquid Chromatography-Mass Spectrometry (LC/MS)
|
Baseline (pre-dose), and Days 1, 3, 7, 14, and 28 post-dose.
|
|
Plasma Carbamoyl Aspartate Concentration
Tijdsspanne: Baseline (pre-dose), and Days 1, 3, 7, 14, and 28 post-dose.
|
Plasma concentrations of carbamoyl aspartate will be quantified using Liquid Chromatography-Mass Spectrometry (LC/MS).
|
Baseline (pre-dose), and Days 1, 3, 7, 14, and 28 post-dose.
|
|
Immunogenicity of a single IV dose of AD-NP1
Tijdsspanne: Baseline (pre-dose) and Days 1, 7, 14, 28, 90, and 180 post-dose
|
Determined by measuring levels of circulating anti-drug antibody in blood samples
|
Baseline (pre-dose) and Days 1, 7, 14, 28, 90, and 180 post-dose
|
|
Apparent Volume of Distribution (Vd) as a pharmacokinetics (PK) parameter
Tijdsspanne: Baseline (pre-dose) up to Day 60 post-dose
|
Volume of distribution calculated during the terminal elimination phase following administration, to be measured in Liters (L) or Liters per kilogram (L/kg)
|
Baseline (pre-dose) up to Day 60 post-dose
|
Medewerkers en onderzoekers
Sponsor
Sponsor
Medewerkers
Medewerkers
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Studie start
Primaire voltooiing (Geschat)
Primaire voltooiing
Studie voltooiing (Geschat)
Studie voltooiing
Studieregistratiedata
Eerst ingediend
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Eerst geplaatst
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update geplaatst
Laatste update ingediend die voldeed aan QC-criteria
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Andere studie-ID-nummers
Andere studie-ID-nummers
- 25-1584
- PR250528 (Ander subsidie-/financieringsnummer: DOD-DEPARTMENT OF DEFENSE)
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .